Pre-IPO Ziyond Pharmaceutical - Profitability Has Not yet Stabilized
Ziyond's business model focus on wide product coverage and online growth, but face challenges due to market size and profitability concerns.Based...
104 Views
Ziyond Pharmaceutical (ZYND HK): Synthetic Expert Call Transcript (11 Jul 2026)
Gross margin compression from 71.8% in 2023 to 66.1% in Q1 2026 is primarily driven by a structural shift from high-margin hospital channels to...
95 Views
IPO Databook: Ziyond Pharmaceutical (HK) - Jul 2026
Ziyond Pharmaceutical is a specialized topical dermatology company in China, offering category-leading products. It seeks HKEX listing to fund...
133 Views
No more insights